- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Renal Cell Carcinoma | Clinical
Roundtable Discussion: Rini Reviews Later-Line Immunotherapy and TKI Combinations in Refractory RCC
December 02, 2021
Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.
Behind the FDA Approval: Belzutifan for VHL-Associated Renal Cell Carcinoma
November 23, 2021
In an interview with Targeted Oncology, Eric Jonasch, MD, discussed the impact belzutifan has had on the VHL-assocaited renal cell carcinoma space, along with unmet clinical needs the agent is addressing.
Behind the FDA Approval: Adjuvant Pembrolizumab for Subgroup of Patients With RCC
November 20, 2021
In an interview with Targeted Oncology, Viraj Master, MD, PhD, FACS , discussed how adjuvant pembrolizumab may impact the treatment landscape of renal cell carcinoma.
Post-Hoc Analysis Shows Adverse Events With First-line Nivolumab Plus Cabozantinib Are Manageable
November 18, 2021
In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.
FDA Approves Adjuvant Pembrolizumab for Renal Cell Carcinoma
November 18, 2021
The FDA has approved adjuvant pembrolizumab for the treatment of renal cell carcinoma with an intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
Modified Ipilimumab Dosing in Ipilimumab/Nivolumab Combo Improves Toxicity in Advanced RCC
November 13, 2021
A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.
Global Phase 3 Study Explores Belzutifan/Lenvatinib Doublet in Advanced RCC
November 11, 2021
The novel combination of belzutifan and lenvatinib will be tested against cabozantinib in a phase 3 clinical trial of patients with advanced renal cell carcinoma.
Viability of Cytoreductive Nephrectomy Followed by Active Surveillance in mRCC Upheld
November 08, 2021
Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.
Study Explores Addition of HIF-2α Inhibitor or Anti-CTLA-4 Therapy to Pembrolizumab Plus Lenvatinib in ccRCC
November 08, 2021
The combination of lenvatinib and pembrolizumab is the current standard of care for ccRCC, however, most patients still experience disease progression. The addition of a third agent may lead to improvement in outcomes.
With NIVO + IPI, Advanced RCC Survival Approaches 5 years
November 07, 2021
Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.